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INVITED REVIEW
The US Food and Drug Administration (FDA) is
charged by Congress under the Federal Food, Drug
and Cosmetic Act with the responsibility of regulating
medical devices to assure their safety and effectiveness.
Under this law, medical devices intended for human
use are subject to a variety of controls and must be
properly labeled and packaged, be cleared for market-
ing by the FDA, meet their labeling claims, and be
manufactured in accordance with good manufacturing
practices. When Congress established the FDA’s cur-
rent authority in device regulation in 1976, it recog-
nized that the discovery and development of new
devices would require exemption from many of these
requirements that apply to devices in commercial dis-
tribution. Accordingly, Congress authorized the FDA
to exempt investigational devices from certain require-
ments of the Federal Food, Drug and Cosmetic Act.
This legal authority and the investigational device
exemptions (IDE) regulation that implements it are
intended “to encourage, to the extent consistent with
the protection of public health and safety and with eth-
ical standards, the discovery and development of use-
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ful devices intended for human use, and to that end to
maintain optimum freedom for scientific investigators
in their pursuit of this purpose.”1,2
Conducting a clinical investigation of a medical
device requires approval under the IDE regulation
before the study begins, with the exception of some
studies that are specified in the regulation.3 An inves-
tigation is a clinical investigation or research, which
involves one or more subjects, to determine the safety
or effectiveness of a device. A clinical study is exempt
from the IDE regulation if the device is used or inves-
tigated in accordance with the indications in the
approved labeling. For example, a comparative study
of two endovascular stents for implantation in the
common iliac artery for the treatment of stenosis as a
result of atherosclerotic disease in which both devices
are approved for that indication would not require the
submission of an IDE application. The local institu-
tional review board (IRB) may require approval of the
study at its discretion. In contrast, if a study is designed
to compare two stents for the creation of an intrahep-
atic portosystemic shunt for prophylaxis of variceal
bleeding and one stent is approved for that indication
and the other is not, then an IDE application would be
required. Both FDA and IRB approval would be
required before the initiation of the study.
The degree of risk involved in the study deter-
mines the level of regulatory control required. A non-
significant risk study may be approved by the local
IRB. A significant risk study, that is, one which “pre-
sents a potential for serious risk to the health, safety or
welfare of a subject,”4 requires approval of an IDE
application by the FDA and may not be conducted
without the approval of both the IRB and the FDA.
In either case, the IDE regulation provides for the
procedures for the conduct of clinical investigations of
devices, including informed consent for all patients,
adequate patient and data monitoring, and mainte-
nance of necessary records and reports. The investiga-
tions must meet the regulatory requirements regard-
ing ethical conduct of human studies, requirements
which adhere to the ethical guidelines of the World
Medical Association Declaration of Helsinki on the
protection of human subjects in biomedical research.
This paper discusses the pre–IDE process and the
content of IDE applications to the FDA for the
approval of studies that pose a significant risk. An
overview of the regulation of medical devices by the
FDA has recently been presented elsewhere.5
FDA REVIEW OF IDE APPLICATIONS
Within the FDA, the regulation of devices is the
responsibility of the Center for Devices and
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Radiological Health. Within the center, the evaluation
of applications for approval of clinical investigations,
commercial marketing, and labeling of cardiovascular
devices is performed by the Division of Cardiovascular,
Respiratory and Neurological Devices in the Office of
Device Evaluation. The review team for an IDE appli-
cation may include medical professionals, scientists,
engineers and biostatisticians, as appropriate for each
application. In addition, there are two committees
within the division that serve as resources for the
review teams: the Pre-Clinical Trials Board and the
Clinical Trials Board. The Pre-Clinical Trials Board is
composed of pathologists, physiologists, and biomed-
ical engineers and provides guidance on animal testing.
The Clinical Trials Board reviews clinical research pro-
tocols submitted to the division. The members of the
board are medical officers and other persons on the
staff of the center with experience in the review of
investigational protocols for cardiovascular devices,
such as senior reviewers and biostatisticians. The meet-
ings provide a forum for the discussion of the applica-
tion among the primary reviewers and the members of
the board who may not be directly involved in the
review of the application. The medical specialties cur-
rently represented on the board are anesthesiology,
cardiology, cardiovascular and thoracic surgery,
nuclear medicine, pathology, and radiology.
The FDA is also assisted in its review of device
applications by a system of external experts who
review critical issues and serve in an advisory role.
This Medical Devices Advisory Committee is com-
posed of experts in a broad range of medical special-
ties. The committee is subdivided into 16 panels
according to clinical area and device specialty, such
as the Circulatory System Devices Panel. The prima-
ry role of the panel is the review of certain market-
ing applications, but it may also provide advice on
device classification, potential risks, development of
study protocols, and the content of guidelines or
guidance documents. The advisory panels provide
the FDA with scientific and medical expertise from
the user community, which helps to ensure that the
decision-making of the FDA reflects the state-of-
the-art in medical practice and technology. In addi-
tion, the FDA benefits from its interactions with
professional societies, the medical community, and
device manufacturers, and from the discussion of
issues of mutual concern.
PRACTICE OF MEDICINE VERSUS CLINI-
CAL INVESTIGATION
Historically, the FDA has purposefully avoided
regulating the practice of medicine and has taken the
position that physicians must have the latitude to do
whatever is in the best interests of their patients.6 The
FDA’s articulated policy states that “good medical
practice and patient interests require that physicians
be free to use commercially available drugs, devices
and biologics according to their best knowledge and
judgment. If a physician uses a product for an indica-
tion not in the approved labeling, he or she has the
responsibility to be well informed about the product
and to base its use on a firm scientific rationale and
on sound medical evidence, and to maintain records
of the product’s use and effects.”7 Use of a legally
marketed device for an “off-label” indication as part
of the practice of medicine does not require clearance
through the FDA but may require review by an IRB,
depending on the individual IRB requirements.
In contrast, research that involves one or more
subjects to determine the safety or effectiveness of a
device is not within the realm of the practice of med-
icine, whether or not the device is legally marketed.
These clinical investigations must be conducted in
accordance with the IDE regulation. For example,
because the safety and effectiveness of endovascular
grafts have not been shown, these devices should
only be used as part of a clinical investigation.
Specific questions as to whether a particular use of a
device is considered practice of medicine or is a clin-
ical investigation may be directed to the physician’s
IRB or the FDA.
SIGNIFICANT RISK STUDY VERSUS 
NONSIGNIFICANT RISK STUDY
If the use of a device is investigational, then the
distinction must be made as to whether the study
constitutes a significant risk study or a nonsignificant
risk study. This decision is crucial because it deter-
mines the level of regulatory control to which the
study will be subject.8,9 A significant risk study is
defined by the IDE regulation as one which “pre-
sents a potential for serious risk to the health, safety,
or welfare of a subject.”4 The determination of sig-
nificant risk is on the basis of the nature of harm that
may result from the use of the device in the investi-
gation, including the potential harm that could be
caused by any procedure used in conjunction with
the device. It is the risk of the study, not the device,
that is the issue. For example, if a device is implant-
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ed as part of a surgical procedure, the potential for
harm from the surgery is considered in determining
whether the study constitutes a significant risk. In
addition, the risk should be determined on the basis
of absolute risks, not risk relative to an existing
device. For example, it would be inappropriate to
categorize a study of a covered stent as a nonsignif-
icant risk study on the basis of the common usage of
bare stents or the perceived advantages over current
stents. The absolute risk—that failure could be life-
threatening or injurious—dictates that it is a signifi-
cant risk study.
The local IRB makes the determination as to
whether a study is a significant risk or nonsignificant
risk study. However, the FDA retains the final
authority to make that determination. If a study is a
nonsignificant risk study, then the IRB acts as an
FDA surrogate and may approve the study without
direct FDA involvement.10 If a study constitutes a
significant risk, the sponsor must explicitly apply to
the FDA for approval of an IDE application. The
study may not proceed unless both the FDA and the
IRB approve the IDE application, but the sponsor
need not wait for IRB approval before submitting
the IDE application to the FDA, nor vice versa. As
an example, vascular stents and vascular graft pros-
theses are considered significant risk devices as a
result of the inherent risks that are associated with
the use of these devices. Both FDA and IRB
approval would be required before the initiation of
a study that involved these devices.
OVERVIEW OF THE PRE–IDE PROCESS
AND IDE APPLICATIONS
Once a determination is made that a study is a
significant risk study, an IDE application must be
submitted to the FDA and approved or conditional-
ly approved before the clinical study may begin. The
Investigational Device Exemptions Manual reviews
the regulatory requirements, discusses practical
issues related to the submission of an IDE applica-
tion, and contains other useful documents from the
FDA, including copies of the pertinent regulations
(Table I). A listing of sources of information is
included in Table II. The IDE application may be
submitted by the manufacturer of a device for the
collection of data to support a future marketing
application or by a responsible investigator who
wishes to conduct an investigation of the safety and
effectiveness of a device. Early and continued inter-
actions between the sponsor and the FDA through
the pre–IDE process is encouraged to expedite the
development of an IDE application.
Table I. Pertinent regulations
Investigational device exemptions 21 CFR Sect 812.
Protection of human subjects 21 CFR Sect 50.
Institutional review boards 21 CFR Sect 56.
Once an IDE application has been filed, the FDA
has 30 days in which to make a determination of
whether to approve, conditionally approve, or disap-
prove the application. That decision is made on the
basis of the adequacy of the device description, the
report of prior investigations, the investigational
plan, and compliance with the applicable portions of
the IDE regulation. The clinical investigation may
be initiated once the study has been approved by
both the FDA and the local IRB.
An application that receives conditional approval
requires, within 45 days, the submission of a supple-
ment that contains the information requested in the
conditional approval letter. The clinical investigation
may be initiated once the FDA has issued a condi-
tional approval decision and need not wait for full
approval, provided that the IRB has also approved
the study. If the conditions of approval are not met
within the 45-day period, the FDA may propose dis-
continuation of the study.
If the FDA disapproves the application, the letter
to the sponsor will delineate the deficiencies and
identify the information necessary to correct the
application. The sponsor then may submit an
amendment to the IDE application that addresses
each deficiency.
After approval, there are a number of required
communications with the FDA. For example, sup-
plements are submitted for the addition of new insti-
tutions or facilities, for changes in the investigation-
al plan or device, and for reports on the progress of
the study. The intent of these communications is to
assure the continued protection of the study subjects
and to maximize the sharing of vital information as
the study progresses.
THE PRE–IDE PROCESS
The purpose of the pre–IDE process is to proac-
tively identify and address issues and concerns
regarding the development, evaluation, and perfor-
mance of an investigational device. This process is
intentionally flexible and may be adapted to meet
the needs of the individual sponsor. The following
discussion illustrates the types of data and informa-
tion that may be presented in a pre-IDE application
or during a pre-IDE meeting with the FDA,
depending on the stage of development of the
device at the time of the meeting. The discussion
also reflects the types of questions that the FDA may
have regarding a device and the types of information
that may be needed to adequately evaluate the sci-
entific justification of the formal IDE application.
This information ahould serve as a guide for the
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The pre-IDE interactions between the sponsor and
the FDA occur during the sponsor’s development of a
device and the clinical research protocol. Product
development is a dynamic process, and interactions
with the FDA may be initiated at any stage of the
developmental process. Communication with the
FDA through a pre-IDE application before the formal
submission of an IDE application helps to identify the
issues and concerns that will need to be addressed in
the IDE application and facilitates approval of the IDE
application. These early informal interactions may be
implemented through teleconferences, personal meet-
ings, or written submissions and are considered strict-
ly confidential as are formal IDE applications. The
extent of pre-IDE interactions will depend on the
complexity and novelty of the device and the related
issues and, to some extent, on the experience of the
sponsor in preparing IDE applications. Early interac-
tion during the development process will help to make
clear to the sponsor what the FDA’s expectations will
be for the content of a particular IDE application.
In the formal IDE application, the proposed
investigational plan must be adequately justified on
the basis of the report of prior investigations includ-
ed in the application (ie, all prior laboratory, animal,
and clinical testing of the device). In addition, the
application must establish the following: (1) the
rights, safety, and welfare of study subjects will be
protected; (2) the anticipated benefits or the impor-
tance of the knowledge to be gained outweigh the
risks to the research subjects; (3) the investigation is
scientifically sound with the expectation that useful
data will be gathered in the study; (4) the distribu-
tion of the investigational devices will be controlled;
and (5) adequate records and reports will be main-
tained. In evaluating an IDE application, the FDA
understands that not all can be known about the
device before the study. However, safety issues are to
be addressed by the bench and preclinical testing
before human use testing, and due care in the device
design, investigational planning, and protection of
human subjects, including adequate informed con-
sent from the study subjects, is required.
In preparing a clinical protocol, one should con-
sider a feasibility study involving a small number of
study subjects as the first step.11 The purpose of
these studies is to initiate investigator experience,
establish an operator learning curve, assess design
adequacy, address specific safety issues, further
define the clinical protocol, and evaluate the poten-
tial efficacy of the device. The feasibility study may
be subsequently expanded to a full study by submis-
sion of an IDE supplement.
preparation, general approach, and motivation for
early contact with the FDA.
The pre–IDE process is particularly useful in
developing the report of prior investigations.
Voluntary standards and FDA guidance documents
may be helpful in developing this section. However,
for innovative technologies, it is not only necessary to
list the tests to be conducted but also to show that
the testing plan is appropriate and comprehensive.
One method to identify appropriate testing is to
define the device and its intended use, evaluate the
potential failure modes and clinical complications,
and determine the testing needed to address each
identified issue. Once the testing strategy is defined,
the appropriate test methodologies may be devel-
oped, including bench, animal, and human studies.
The basic information clearly defines the device
and its intended use. The device description includes
a physical description of the device, including all the
accessories, such as delivery catheters and adjunctive
equipment, and a description of any modifications
made to currently marketed devices used with or as
part of the device. The information should include
the following descriptions: what the device is intend-
ed to do and under what conditions or environments;
how it does what it is intended to do; how long it
should be able to do what it is intended to do; and for
what patient population it is intended. Literature sup-
port should be provided where appropriate.
This basic information then can be used to iden-
tify the appropriate types of tests that should be con-
ducted, and it serves as a foundation for the devel-
opment of a testing strategy for the device. In devel-
oping the test plan, the potential safety and
effectiveness issues are identified through an analysis
of the potential failure modes of the device, and a list
of tests that address each issue is complied. In addi-
tion, tests are developed that are designed to charac-
terize the device and show conformance to design
specifications. The section should include a discus-
sion of the device design and review process and the
design analysis, design implementation, and verifica-
tion or validation processes.
Once the appropriate tests have been identified,
the test methodologies can be developed on the basis
of the intended use of the device and the anticipated
safety and effectiveness issues. The rationale and jus-
tifications of the test methodologies should be on the
basis of statistical or clinical rationale or both, with
literature support when appropriate. The testing may
include preclinical in vitro, preclinical in vivo, and
clinical investigations. In general, each test method
should state the purpose of the test with a clear state-
ment of the hypothesis to be tested and should iden-
tify the safety and effectiveness issue that it is intend-
ed to address and the relevant parameters and vari-
ables to be assessed. The test description should show
how the study design answers the question posed.
Once sufficient preclinical data are collected, the
report of prior investigations may be finalized. The
report of prior investigations should follow the log-
ical progression of device development and testing
and should include reports of all prior laboratory
and animal testing of the device and any prior clini-
cal experience with the device. It should be compre-
hensive and should provide adequate information to
show the acceptability of the results obtained to jus-
tify the proposed clinical investigation. There also
must be an indication as to whether nonclinical stud-
ies were performed in compliance with applicable
requirements in the good laboratory practice regula-
tions. The report also must include the following: a
bibliography of all publications, whether adverse or
supportive, that are relevant to an evaluation of the
safety or effectiveness of the device; copies of all
published and unpublished adverse information;
copies of other significant publications if requested
by an IRB or FDA; and a summary of all other
unpublished information (whether adverse or sup-
portive) that is relevant to an evaluation of the safe-
ty or effectiveness of the device.12
The investigational plan may be finalized as the
report of prior investigations is completed. The
requirements for the investigational plan are delin-
eated in the IDE regulation and should be presented
in detail, including the purpose, research protocol,
risk analysis, description of the device, and consent
materials. As listed in the regulation, the purpose
states the intended use of the device and the objec-
tives and duration of the investigation. The written
protocol describes the methodology to be used and
an analysis of the protocol showing that the investi-
gation is scientifically sound. The risk analysis
includes a description and analysis of all the increased
risks to which the subjects will be exposed by the
investigation, the manner in which these risks will be
minimized, a justification for the investigation, and a
description of the patient population, including the
number, age, sex, and condition of the subjects.
Copies of all forms and informational materials to be
provided to the subjects to obtain their informed
consent should be included.13
THE IDE APPLICATION
Once adequate information is available to justify
the initiation of a clinical investigation, an IDE appli-
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for which a manufacturer has received FDA clear-
ance or approval for marketing.
To assist the HCFA in its coverage decisions, the
FDA assigns each device with an approved IDE
application to one of two categories: experimen-
tal/investigational devices (category A) or nonex-
perimental/investigational devices (category B).
The category A device is an innovative device for
which “absolute risk” of the device type has not
been established—that is, initial questions of safety
and effectiveness have not been resolved and the
FDA is unsure whether the device type can be safe
and effective. Category A devices are excluded from
Medicare coverage. The category B device is a device
for which the incremental risk is the primary risk in
question—that is, underlying questions of safety and
effectiveness of that device type have been
resolved—or it is known that the device type can be
safe and effective because, for example, other manu-
facturers have obtained FDA approval for that device
type. The HCFA will consider coverage of a catego-
ry B device for Medicare beneficiaries who partici-
pate in an approved clinical investigation. The inten-
tion is to provide Medicare beneficiaries with greater
access to advances in medical technology and to
encourage clinical researchers to conduct high-qual-
ity studies of newer technologies. As a general rule
for all medical care, the HCFA has the authority to
conduct a separate assessment of the appropriateness
of an item or a service for Medicare coverage,
including whether it is reasonable and necessary
specifically for its intended use for Medicare benefi-
ciaries.15,16
DILEMMAS IN THE REGULATION OF
NEW TECHNOLOGIES
The introduction of new technologies also pre-
sents new clinical and regulatory concerns that must
be addressed. These may relate to the risk-benefit
analysis, the safety and effectiveness of the device, or
the clinical evaluation and management of patients.
The introduction of endovascular grafts for the
treatment of abdominal aortic aneurysms provides a
number of examples. The balance of risks and bene-
fits for endovascular grafts differs from that for the
alternative therapy—open surgical repair. Placement
of endovascular grafts may have a lower periopera-
tive morbidity and mortality rate as compared with
open surgical repair, but the endovascular grafts may
not be as effective because they have the potential
for the incomplete exclusion of an aneurysm. There
are new safety considerations, such as the potential
for device migration or strut fracture. There are also
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cation may be submitted to the FDA for approval of
a human study of the device. The application may be
for a feasibility study11 or for a larger and more com-
prehensive investigation. The requirements for the
content of the application are delineated in the IDE
regulation.14
The IDE Manual contains a copy of the admin-
istrative checklist used by the reviewers. By observ-
ing the requirements, one may prepare a complete
application for submission to the FDA. The FDA
review of the application is not merely a review of
the checklist but also considers the device descrip-
tion, the intended patient population, alternative
procedures or courses of treatment, associated risks
and benefits and their magnitudes, whether useful
data will be collected from the study as planned,
whether the device is a relatively new technology or
a modification to an existing device, and whether the
investigation is scientifically sound.
A time line that projects the completion of the
bench or animal testing should also be included
because the degree of completeness of the bench or
animal testing required for approval of an IDE appli-
cation depends on the details of the application being
submitted. For example, the requirements may be
less strict for the initiation of a small feasibility study
with the understanding that a higher level of com-
pletion will be required for expansion to a larger or
more definitive study. For a device intended for com-
mercial marketing, additional testing may need to be
completed before the time the marketing application
is submitted to the FDA. In that case, the application
should identify the information that will be collected
for the expected marketing application.
REIMBURSEMENT BY THE HEALTH
CARE FINANCING ADMINISTRATION
The Health Care Financing Administration
(HCFA) does not provide coverage for experimental
devices but may provide reimbursement for nonex-
perimental investigational devices provided that the
device is used in accordance with the IDE regula-
tion. The HCFA recognizes that there are devices
that are refinements or replications of existing tech-
nologies. Although an approved IDE application
may be required for studies of the safety and effec-
tiveness of a particular device, there may be scientif-
ic evidence that similar devices can be safe and effec-
tive. If the FDA has determined that the device type
can be safe and effective, the devices will be consid-
ered for possible coverage. For example, the HCFA
will consider for possible coverage those investiga-
tional devices that are of the same type as a device
questions of effectiveness, such as whether the
devices adequately exclude the aneurysms, maintain
adequate blood flow, and prevent or reduce the risk
of rupture. Evaluation of the devices after implanta-
tion requires the development of a rational follow-
up protocol that includes clinical evaluation and
imaging studies to document effectiveness and to
detect clinical events, such as persistent blood flow
into the aneurysm or aneurysm enlargement. In the
case of endovascular grafts, the clinical importance
and incidence of adverse sequela related to persistent
perigraft leaks or retrograde flow from collateral ves-
sels is unclear. The regulatory approach to these
issues may change as both the technology and the
understanding of the devices by the clinical commu-
nity and the FDA evolve.
THE INDIVIDUAL SPONSOR-
INVESTIGATOR
Although the development of an IDE application
may seem a daunting proposition for a sponsor-inves-
tigator, interactions with the FDA and the use of avail-
able resources make this task practicable (Table II).
The FDA recognizes that individual investigators may
not have the same goals in conducting clinical studies
as do manufacturers. As such, studies may be designed
differently by sponsor-investigators as compared with
manufacturers. If so, the reports of prior investigations
may also differ from those in IDE applications spon-
sored by manufacturers. However, adequate informa-
tion to justify the use of the device in the proposed
patient population must be provided, regardless of the
nature of the sponsor or the study. The pre–IDE
approval process may be particularly helpful to the
sponsor-investigator in providing feedback on a “draft
IDE application,” particularly because sponsor-investi-
gators generally have less experience than manufactur-
ers in the preparation of IDE applications.
Research conducted in accordance with the IDE
regulation benefits the public health because the
FDA acts as a repository for information on device
development and clinical investigations. The sharing
of information directly with the FDA enhances the
knowledge of FDA personnel regarding devices cur-
rently under development. Although the FDA main-
tains strict confidentiality regarding IDE applica-
tions and the results of the clinical investigations, the
knowledge gained assists the FDA in its review of
related devices and may affect the FDA’s require-
ments for and interactions with other sponsors or
manufacturers. For example, difficulties encoun-
tered by a clinician in using a device in a particular
patient population may lead to the FDA recom-
mending that other sponsors address or consider
restricting the use of their device in those patients.
The FDA also may take steps to ensure that the
labeling for the device specifically addresses the use
of the device for those patients.
Many clinicians are frustrated that devices may
be available abroad before approval is received for
marketing in the United States. The individual
investigator can be proactive in addressing the issue
of availability of devices in the United States by
understanding the system and by actively participat-
ing in the design and conduct of clinical investiga-
tions. This will help to ensure that scientifically valid
information is provided to the FDA in support of
marketing applications.
Endovascular grafts: an example. As a simpli-
fied hypothetical example, consider a proposed
investigation in which abdominal aortic aneurysms
would be treated with an endovascular graft con-
structed with legally marketed devices—ie, stents
and vascular graft materials. The principal investiga-
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Table II. Sources of information from the Food
and Drug Adminstration
Center for Devices and Radiological Health web site:
http://www.fda.gov/cdrh/
Investigational Device Exemptions Manual (HHS Publication
FDA 96-4159):
http://www.fda.gov/cdrh/manual/idemanul.html or
WordPerfect 6.1 file on a 3.5-inch floppy disk from the Division
of Small Manufacturers Assistance by faxing a request to 301-
443-8818 and addressing it to “Publications”
Guidance on IDE policies and procedures (this includes discus-
sions of emergency use of unapproved medical devices and com-
passionate use of investigational devices):
http://www.fda.gov/cdrh/ode/idepolcy.html
Guidance on the review of investigational device exemptions (IDE)
applications for feasibility studies, IDE Guidance Memorandum
No. #D89-1, 5/17/89: http://www.fda.gov/cdrh/d891.html
Device Advice, a self-service site for information on device regu-
lation: http://www.fda.gov/cdrh/devadvice/
Phone listings for review divisions in the Office of Device
Evaluation: http://www.fda.gov/cdrh/organiz.html#ODE
Division of Small Manufacturers Assistance:
http://www.fda.gov/cdrh/dsma/dsmamain.html
FDA/CDRH/OHIP/DSMA (HFZ-220), 1350 Piccard Dr,
Rockville, MD 20850-4307; phone 800-638-2041; fax: 301-
443-8818; dsma@cdrh.fda.gov.
Although the current Internet addresses for these sources of
information are provided, the same information may be
obtained from the Division of Small Manufacturers Assistance.
tor learned the technique during a fellowship with a
leader in the specialty and wanted to offer this treat-
ment option to patients who are not surgical candi-
dates. The investigator prepared a protocol for
review by the IRB. The IRB determined that FDA
approval would be required, but it did approve the
study subject to FDA review. The investigator con-
tacted one of the FDA reviewers who handles these
types of devices for assistance in drafting the IDE
application. The reviewer, in addition to providing
verbal advice during their conversation, forwarded a
package of information to the investigator.
The investigator’s major task in the preparation of
an IDE application was the development of the report
of prior investigations—the section that provided the
justification for the study. This section required the
most additional effort beyond that which was already
required for the application prepared for IRB review.
The investigator approached the development of this
section by considering such questions as: are the
device or the components of the device legally mar-
keted in the United States for any intended use; how
will the marketed device be modified for use in the
study; what concerns need to be addressed as a result
of the modifications; does the new intended use raise
additional concerns as compared with the labeled
intended use; what are the alternative treatment
options for the patients defined by the selection crite-
ria in the protocol; how long is the device intended to
function or be used; and is information available from
the published literature, the manufacturer, or person-
al experience to address all concerns and support the
assumption that the benefits to the defined patient
population should outweigh the risks?
In this example of the endovascular graft, the fol-
lowing points were considered in drafting the report
of prior investigations:
1. The device was to be constructed by combining
legally marketed devices, each of which was indi-
cated for use in the vascular system. Thus, there
were no biocompatibility issues because those
issues would have been addressed as part of the
marketing applications for the devices.
2. The devices were to be modified by sewing them
together, followed by resterilization in accor-
dance with the labeling for both devices. The
sewing of the devices together raised the ques-
tion as to whether the devices would stay togeth-
er during the manipulations required for implan-
tation and over time. There were no new con-
cerns related to the sterilization of the device
because this was to be performed in accordance
with the device labeling for both devices.
3. The new intended use required the anchoring of
the prosthesis in place intraluminally. This raised
questions, such as whether the device would
migrate, erode through the vessel wall, fail as a
result of fatigue, and adequately exclude the
aneurysm.
4. The protocol was designed to include only
patients who presented a high surgical risk. Thus,
the selection criteria were adequately defined to
exclude all patients who could have been treated
with standard surgical repair. Given that the
patients did not have a viable treatment option,
the risks associated with the endovascular repair
were compared with the risk of aneurysm rupture
rather than the risk of standard surgical therapy.
5. The device was intended to function for the life of
the patient. To define the life of the patient, the
investigator considered what the expected life of
the patient population would have been without
treatment. The fact that this was a “high-risk”
population allowed for the consideration of a
shorter time frame, perhaps 2 years rather than 10
to 30 years for good surgical candidates.
The investigator identified the appropriate pub-
lished literature, information from the manufactur-
ers of the component devices, and personal experi-
ence to address these issues and to confirm the
assumption that the benefits to the patients would
outweigh the risks. Fortunately for the investigator
and the potential patients, this could be accom-
plished with little or no additional preclinical testing
because the experience of the mentor, the personal
experience of the investigator, the available informa-
tion on the legally marketed device components, and
other information available in the literature allowed
the investigator to adequately address all concerns to
justify the initiation of a feasibility study in this lim-
ited patient population. In the future, if the investi-
gator proposed treating patients at lower risk, addi-
tional information would be needed to address the
different balance between the risks and benefits and
to show that the device would be expected to func-
tion for the same duration as a standard surgical
repair. Some of that information would be collected
during this feasibility study in the patients at high
risk.
The investigator prepared a draft of the IDE
application that included the completed report of
prior investigations, the clinical protocol previously
presented to the IRB, and the additional informa-
tion delineated in the IDE Manual. This draft was
identified as a pre-IDE application and mailed to the
IDE Document Mail Center to the attention of the
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reviewer previously contacted. The reviewer read
the document and provided suggestions for revi-
sions to the investigator by facsimile within 60 days.
The sponsor-investigator made the suggested
changes, submitted the official IDE application, and
within 30 days received approval to begin the inves-
tigation. The IRB also had approved the final clini-
cal protocol, and the study commenced. The spon-
sor conducted the investigation in accordance with
the IDE regulation. By gaining FDA approval of the
investigation, the IRB remained in conformance
with its responsibilities and allowed for potential
reimbursement through the HCFA for the devices,
even though they are not used in accordance with
their approved labeling.
SUMMARY
The purpose of the IDE regulation is to encour-
age the discovery and the development of useful
devices, intended for human use, to the extent con-
sistent with the protection of public health and safe-
ty and with ethical standards. Investigators should
be aware of the distinctions between significant and
nonsignificant risk studies and between clinical
investigations and practice of medicine. The FDA
can assist in the development of a device and the
investigational plan whether the sponsor is a manu-
facturer or an individual investigator. The FDA
encourages active participation by clinicians in the
development and regulation of medical devices as
part of the collaborative effort required both for
medical innovation and for the dissemination of new
products to the broader market.
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